Daniel de Santa Inez

Mr. Daniel de Santa Inez

Universidade de Sao Paulo
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DIDaniel de Santa Inez
Daniel de Santa Inez
Cesar Seigi FuziwaraCesar Seigi Fuziwara
Cesar Seigi Fuziwara
KSKelly Saito
Kelly Saito
EKEdna T Kimura
Edna T Kimura
Thyroid cancer is the most common endocrine malignancy, and the characterization of the genetic alterations in coding-genes that drive thyroid cancer are well consolidated in MAPK signaling. In the context of non-coding RNAs, microRNAs (miRNAs) are small non-coding RNAs that, when deregulated, cooperate to promote tumorigenesis by targeting mRNAs, many of which are proto-oncogenes and tumor suppressors. In thyroid cancer, miR-146b-5p is the most overexpressed miRNA associated with tumor aggressiveness and progression, while the antisense blocking of miR-146b-5p results in anti-tumoral effect. Therefore, inactivating miR-146b has been considered as a promising strategy in thyroid cancer therapy. Here, we applied the CRISPR/Cas9n editing system to target the MIR146B gene in an aggressive anaplastic thyroid cancer (ATC) cell line. For that, we designed two single-guide RNAs cloned into plasmids to direct Cas9 nickase (Cas9n) to the genomic region of the pre-mir-146b structure to target miR-146b-5p and miR-146b-3p sequences. In this plasmidial strategy, we cotransfected pSp-Cas9n-miR-146b-GuideA-puromycin and pSp-Cas9n-miR-146b-GuideB-GFP plasmids in KTC2 cells and selected the puromycin resistant + GFP positive clones (KTC2-Cl). As a result, we observed that the ATC cell line KTC2-Cl1 showed a 60% decrease in the expression of miR-146b-5p compared to the control, also showing reduced cell viability, migration, colony formation, and blockage of tumor development in immunocompromised mice. The analysis of the MIR146B edited sequence shows a 5 nt deletion in the miR-146b-5p region and a 1 nt deletion in the miR-146b-3p region in KTC2-Cl1. Thus, we developed an effective CRISPR/Cas9n system to edit the MIR146B miRNA gene and reduce miR-146b-5p expression which constitutes a potential molecular tool for the investigation of miRNAs function in thyroid cancer.

23 October 2026 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
STSara Carolina Vieira Terra
Sara Carolina Vieira Terra
CBCynthia Silvia Bartolomeo
Cynthia Silvia Bartolomeo
SSSofia Mila Cantu de Sales
Sofia Mila Cantu de Sales
DIDaniel de Santa Inez
Daniel de Santa Inez
DTDavi Coe Torres
Davi Coe Torres
RSRoberta Stilhano
Roberta Stilhano
Introduction: Peripheral artery disease (PAD) reduces tissue perfusion and causes ischemia, conditions in which hypoxia-responsive pathways have an important adaptive role. Hypoxia- inducible factor 1-alpha (HIF-1α), a central regulator of this response, is tightly controlled by prolyl hydroxylase domain protein 2 (PHD2), encoded by EGLN1. Here, we used an RNA-targeting CRISPR-Cas13d system to downregulate EGLN1 in human umbilical vein endothelial cells (HUVECs) under normoxia and hypoxia. Methods: A PHD2-knockdown (PHD2-KD) HUVEC line was generated by lentiviral delivery of an EGLN1-targeting RNA guide, alongside non-transduced (CTRL) and non-targeting gRNA (NTG) control lines. Molecular and functional assays assessed hypoxia-related signaling, metabolic activity, migration, and sprouting responses under normoxia and hypoxia. results: PHD2-KD HUVECs showed significantly increased VEGFA expression under both normoxia and hypoxia, at the mRNA level (7.0-fold and 5.4-fold, respectively) and protein level (6.6-fold and 9.4-fold, respectively). At early time points (3–12 h), HIF-1α gene and protein levels were elevated, accompanied by reduced inflammatory cytokine levels, with TNF-α becoming undetectable after 48 h. Functionally, PHD2-KD cells showed enhanced proliferation, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and increased sprouting activity, with up to 5.4-fold more sprouts per bead and sprouts up to 2.5-fold longer than controls. Results: Western blotting confirmed a marked reduction in PHD2 protein abundance in PHD2-KD cells relative to both CTRL and NTG cells. PHD2-KD HUVECs exhibited increased VEGFA transcript levels (6.5-fold under normoxia and 5.3-fold under hypoxia) and secreted VEGF concentrations (6.6-fold and 9.4-fold, respectively), together with early increases in HIF1A transcript and HIF-1α protein levels and lower TNF-α concentrations. Functional assays showed higher metabolic activity, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and enhanced sprouting, with up to 7.2-fold more sprouts per bead and sprouts up to 2.7-fold longer than those formed by CTRL. Discussion: CRISPR-Cas13d-mediated EGLN1 targeting reduced PHD2 protein abundance and was associated with higher endothelial metabolic activity, faster wound closure, enhanced sprouting behavior, and lower TNF-α secretion. Conclusion: CRISPR-Cas13d-mediated downregulation of EGLN1/PHD2 was associated with increased pro-angiogenic signaling and improved angiogenesis-related endothelial responses in vitro, supporting RNA-targeting strategies to modulate hypoxia-responsive pathways.